

# Ephraim J Fuchs

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6630733/publications.pdf>

Version: 2024-02-01

51  
papers

5,935  
citations

168829

31  
h-index

223390

49  
g-index

52  
all docs

52  
docs citations

52  
times ranked

4627  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 260-269.	0.2	4
2	HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide. <i>Blood</i> , 2022, 139, 1452-1468.	0.6	52
3	Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 109.e1-109.e8.	0.6	12
4	Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 259.e1-259.e11.	0.6	11
5	Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 406.e1-406.e6.	0.6	4
6	Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. <i>Blood</i> , 2021, 137, 420-428.	0.6	119
7	Engraftment of Double Cord Blood Transplantation after Nonmyeloablative Conditioning with Escalated Total Body Irradiation Dosing to Facilitate Engraftment in Immunocompetent Patients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 879.e1-879.e3.	0.6	0
8	Allogeneic Blood or Marrow Transplantation with Nonmyeloablative Conditioning and High-Dose Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis for Secondary Central Nervous System Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 863.e1-863.e5.	0.6	4
9	The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. , 2020, 8, e000810.		5
10	Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. <i>Blood Advances</i> , 2020, 4, 3913-3925.	2.5	52
11	Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial. <i>Lancet Haematology</i> ,the, 2019, 6, e183-e193.	2.2	111
12	Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1128-1135.	2.0	38
13	Post-transplantation cyclophosphamide to facilitate HLA-haploidentical hematopoietic cell transplantation: Mechanisms and results. <i>Seminars in Hematology</i> , 2019, 56, 183-189.	1.8	8
14	Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1022-1028.	2.0	29
15	Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1099-1102.	2.0	61
16	Human papilloma virus-specific T cells can be generated from naïve T cells for use as an immunotherapeutic strategy for immunocompromised patients. <i>Cytotherapy</i> , 2018, 20, 385-393.	0.3	15
17	Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 126-136.	2.0	33
18	Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 343-352.	2.0	61

#	ARTICLE	IF	CITATIONS
19	Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. <i>Blood Advances</i> , 2018, 2, 299-307.	2.5	69
20	Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?. <i>Blood Advances</i> , 2018, 2, 1180-1186.	2.5	35
21	Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2056-2064.	2.0	32
22	Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 612-617.	2.0	17
23	Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. <i>Haematologica</i> , 2017, 102, 391-400.	1.7	152
24	Haplotype Counting for Sensitive Chimerism Testing. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 427-436.	1.2	10
25	Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. <i>Blood</i> , 2017, 129, 1389-1393.	0.6	69
26	Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2127-2136.	2.0	17
27	Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Children and Adolescents with Fanconi Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 310-317.	2.0	50
28	Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 325-332.	2.0	61
29	Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide. <i>Blood Advances</i> , 2017, 1, 288-292.	2.5	84
30	Related haploidentical donors are a better choice than matched unrelated donors: Point. <i>Blood Advances</i> , 2017, 1, 397-400.	2.5	30
31	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. , 2016, 4, 90.		17
32	How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?. <i>Journal of Hematology and Oncology</i> , 2016, 9, 35.	6.9	78
33	Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 3141-3149.	0.8	212
34	Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide. <i>Seminars in Hematology</i> , 2016, 53, 90-97.	1.8	118
35	Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen–Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 112-118.	2.0	37
36	Modern approaches to HLA-haploidentical blood or marrow transplantation. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 10-24.	12.5	262

#	ARTICLE	IF	CITATIONS
37	Shortened-Duration Tacrolimus after Nonmyeloablative HLA-Haploidentical (NMA haplo) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Facilitates Strategies for Relapse Reduction. <i>Blood</i> , 2016, 128, 831-831.	0.6	3
38	Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. <i>Blood</i> , 2015, 125, 3024-3031.	0.6	259
39	Haplo graft engineering: sculpting to a T. <i>Blood</i> , 2015, 125, 2315-2316.	0.6	1
40	Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. <i>Blood</i> , 2015, 126, 1033-1040.	0.6	565
41	Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. <i>Science Translational Medicine</i> , 2015, 7, 288ra78.	5.8	104
42	Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2115-2122.	2.0	26
43	Mismatched Related and Unrelated Donors for Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1485-1492.	2.0	43
44	Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. <i>Blood</i> , 2014, 124, 3817-3827.	0.6	165
45	Graft-Versus-Host Disease (GVHD) and Survival Outcomes after HLA-Haploidentical (Haplo) Bone Marrow Transplant (BMT) Compare Favorably with Matched Related Donor (MRD), and Matched Unrelated Donor (MUD) BMT Utilizing High-Dose Posttransplantation Cyclophosphamide (PTCy). <i>Blood</i> , 2014, 124, 730-730.	0.6	5
46	Partially Mismatched Transplantation and Human Leukocyte Antigen Donor-Specific Antibodies. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 647-652.	2.0	113
47	5-Azacytidine as Salvage Treatment in Relapsed Myeloid Tumors after Allogeneic Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 754-758.	2.0	58
48	Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. <i>Blood</i> , 2011, 118, 282-288.	0.6	549
49	Improved Survival with Inhibitory Killer Immunoglobulin Receptor (KIR) Gene Mismatches and KIR Haplotype B Donors after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 533-542.	2.0	168
50	HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 641-650.	2.0	1,525
51	Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF- $\kappa$ B. <i>Nature Cell Biology</i> , 2001, 3, 409-416.	4.6	316